{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T08:50:31Z","timestamp":1783759831437,"version":"3.55.0"},"reference-count":27,"publisher":"Pharmaceutical Society of Japan","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,10,1]]},"DOI":"10.1248\/bpb.b21-00393","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T22:12:41Z","timestamp":1633039961000},"page":"1499-1505","source":"Crossref","is-referenced-by-count":9,"title":["Implementation Status of Liver Function Tests for Monitoring Benzbromarone-Induced Hepatotoxicity: An Epidemiological Survey Using the Japanese Claims Database"],"prefix":"10.1248","volume":"44","author":[{"given":"Shungo","family":"Imai","sequence":"first","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Nasuhara","sequence":"additional","affiliation":[{"name":"Division of Hospital Safety Management, Hokkaido University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Momo","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmaceutics, School of Pharmacy, Showa University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Oki","sequence":"additional","affiliation":[{"name":"Division of Hospital Safety Management, Hokkaido University Hospital"},{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kashiwagi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Sato","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Miyai","sequence":"additional","affiliation":[{"name":"Graduate School of Life Science, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hokkaido University"},{"name":"Department of Pharmacy, Hokkaido University Hospital"},{"name":"Global Station for Biosurfaces and Drug Discovery, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garc\u00eda-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. <i>Ann. Rheum. Dis.<\/i>, <b>57<\/b>, 545\u2013549 (1998).","DOI":"10.1136\/ard.57.9.545"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. <i>Nature<\/i>, <b>417<\/b>, 447\u2013452 (2002).","DOI":"10.1038\/nature742"},{"key":"3","unstructured":"3) Masbernard A, Giudicelli CP. Ten years\u2019 experience with benzbromarone in the management of gout and hyperuricaemia. <i>S. Afr. Med. J.<\/i>, <b>59<\/b>, 701\u2013706 (1981)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Stamp LK, Haslett J, Frampton C, White D, Gardner D, Stebbings S, Taylor G, Grainger R, Kumar R, Kumar S, Kain T, Porter D, Corkill M, Cathro A, Metcalfe S, Wyeth J, Dalbeth N. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand. <i>Intern. Med. J.<\/i>, <b>46<\/b>, 1075\u20131080 (2016).","DOI":"10.1111\/imj.13173"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Li S, Yang H, Guo Y, Wei F, Yang X, Li D, Li M, Xu W, Li W, Sun L, Gao Y, Wang Y. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. <i>Sci. Rep.<\/i>, <b>6<\/b>, 33082 (2016).","DOI":"10.1038\/srep33082"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Zhou Q, Su J, Zhou T, Tian J, Chen X, Zhu J. A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study. <i>Int. J. Clin. Pharmacol. Ther.<\/i>, <b>55<\/b>, 163\u2013168 (2017).","DOI":"10.5414\/CP202629"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) van der Klauw MM, Houtman PM, Stricker BHC, Spoelstra P. Hepatic injury caused by benzbromarone. <i>J. Hepatol.<\/i>, <b>20<\/b>, 376\u2013379 (1994).","DOI":"10.1016\/S0168-8278(94)80011-1"},{"key":"8","unstructured":"8) Suzuki T, Suzuki T, Kimura M, Shinoda M, Fujita T, Miyake N, Yamamoto S, Tashiro K. A case of fulminant hepatitis possibly caused by benzbromarone. <i>Nihon Shokakibyo Gakkai Zasshi<\/i>, <b>98<\/b>, 421\u2013425 (2001)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Wagayama H, Shiraki K, Sugimoto K, Fujikawa K, Shimizu A, Takase K, Nakano T, Tameda Y. Fatal fulminant hepatic failure associated with benzbromarone. <i>J. Hepatol.<\/i>, <b>32<\/b>, 874 (2000).","DOI":"10.1016\/S0168-8278(00)80263-9"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Arai M, Yokosuka O, Fujiwara K, Kojima H, Kanda T, Hirasawa H, Saisho H. Fulminant hepatic failure associated with benzbromarone treatment: a case report. <i>J. Gastroenterol. Hepatol.<\/i>, <b>17<\/b>, 625\u2013626 (2002).","DOI":"10.1046\/j.1440-1746.2002.02692.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Lee M-HH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? <i>Drug Saf.<\/i>, <b>31<\/b>, 643\u2013665 (2008).","DOI":"10.2165\/00002018-200831080-00002"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Wang H, Peng Y, Zhang T, Lan Q, Zhao H, Wang W, Zhao Y, Wang X, Pang J, Wang S, Zheng J. Metabolic epoxidation is a critical step for the development of Benzbromarone induced hepatotoxicity. <i>Drug Metab. Dispos.<\/i>, <b>45<\/b>, 1354\u20131363 (2017).","DOI":"10.1124\/dmd.117.077818"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kitagawara Y, Ohe T, Tachibana K, Takahashi K, Nakamura S, Mashino T. Novel bioactivation pathway of benzbromarone mediated by cytochrome P450. <i>Drug Metab. Dispos.<\/i>, <b>43<\/b>, 1303\u20131306 (2015).","DOI":"10.1124\/dmd.115.065037"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Felser A, Lindinger PW, Schnell D, Kratschmar DV, Odermatt A, Mies S, Jen\u00f6 P, Kr\u00e4henb\u00fchl S. Hepatocellular toxicity of benzbromarone: effects on mitochondrial function and structure. <i>Toxicology<\/i>, <b>324<\/b>, 136\u2013146 (2014).","DOI":"10.1016\/j.tox.2014.08.002"},{"key":"15","unstructured":"15) Jansen TLTA, Reinders MK, van Roon EN, Brouwers JRBJ. Benzbromarone withdrawn from the European market: another case of \u201cabsence of evidence is evidence of absence\u201d? <i>Clin. Exp. Rheumatol.<\/i>, <b>22<\/b>, 651 (2004)."},{"key":"16","unstructured":"16) Benzbromarone.: \u2039https:\/\/livertox.nlm.nih.gov\/Benzbromarone.html\u203a, accessed 30 April, 2021."},{"key":"17","unstructured":"17) Yellow Letter PMDA.: \u2039https:\/\/www.pmda.go.jp\/files\/000148219.pdf\u203a, accessed 30 April, 2021."},{"key":"18","unstructured":"18) Torii Pharmaceutical Co. Ltd., Urinorm Tablets (benzbromarone). \u201cPharmaceuticals and Medical Devices Agency website.\u201d: \u2039https:\/\/www.info.pmda.go.jp\/go\/pack\/3949002F1053_2_01\/?view=frame&amp;style=SGML&amp;lang=ja\u203a, accessed 30 April, 2021."},{"key":"19","unstructured":"19) PMDA Alert for proper use of drugs.: \u2039https:\/\/www.pmda.go.jp\/files\/000153602.pdf\u203a, accessed 30 April, 2021."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Nasuhara Y, Sakushima K, Oki H, Yamada T, Iseki K, Umeki R, Endoh A. Analysis of the implementation of blood tests specified in the package insert after prescription of thiamazole. <i>J Patient Saf.<\/i>, <b>16<\/b>, 24\u201329 (2020).","DOI":"10.1097\/PTS.0000000000000227"},{"key":"21","unstructured":"21) JMDC Inc.: \u2039https:\/\/www.jmdc.co.jp\/jmdc-claims-database\u203a, accessed 30 April, 2021."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Koto R, Nakajima A, Horiuchi H, Yamanaka H. Real-world treatment of gout and asymptomatic hyperuricemia: a cross-sectional study of Japanese health insurance claims data. <i>Mod. Rheumatol.<\/i>, <b>31<\/b>, 261\u2013269 (2021).","DOI":"10.1080\/14397595.2020.1784556"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Dalbeth N, Merriman TR, Stamp LK. Gout. <i>Lancet<\/i>, <b>388<\/b>, 2039\u20132052 (2016).","DOI":"10.1016\/S0140-6736(16)00346-9"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Imai S, Momo K, Kashiwagi H, Miyai T, Sugawara M, Takekuma Y. Prescription of colchicine with other dangerous concomitant medications: A nation-wide survey using the Japanese claims database. <i>Biol. Pharm. Bull.<\/i>, <b>43<\/b>, 1519\u20131525 (2020).","DOI":"10.1248\/bpb.b20-00314"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Azevedo VF, Kos IA, Vargas-Santos AB, da Rocha Castelar Pinheiro G, Dos Santos Paiva E. Benzbromarone in the treatment of gout. <i>Adv. Rheumatol.<\/i>, <b>59<\/b>, 37 (2019).","DOI":"10.1186\/s42358-019-0080-x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Cadogan CA, Ryan C, Hughes CM. Appropriate polypharmacy and medicine safety: when many is not too many. <i>Drug Saf.<\/i>, <b>39<\/b>, 109\u2013116 (2016).","DOI":"10.1007\/s40264-015-0378-5"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Imai S, Momo K, Kashiwagi H, Miyai T, Sugawara M, Takekuma Y. Association of the ward pharmacy service with active implementation of therapeutic drug monitoring for vancomycin and teicoplanin\u2014an epidemiological surveillance study using Japanese large health insurance claims database. <i>J. Pharm. Health Care Sci.<\/i>, <b>6<\/b>, 18 (2020).","DOI":"10.1186\/s40780-020-00174-8"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/10\/44_b21-00393\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T04:38:01Z","timestamp":1715143081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/10\/44_b21-00393\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b21-00393","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,1]]},"article-number":"b21-00393"}}